Investor Relations

Latest Financial Results

Q1 2022

Quarter Ended Mar 31, 2022

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Company Overview

Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device.

IR Contacts

Headquarters

Lucid Diagnostics Inc.
One Grand Central
60 East 42nd Street, Suite 4600
New York, NY 10165
T: 212-949-4319
info@luciddx.com

Investor Relations

Adrian K. Miller
Vice President of Investor Relations
AKM@Luciddx.com

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place
New York, NY 10004